Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19

Completed · Phase 2

Conditions studied: Covid-19

In brief

Study to assess the safety and efficacy of STI-5656 (Abivertinib Maleate) plus SOC versus SOC in subjects hospitalized with COVID-19

Key facts

Study ID

NCT04440007

Run by

Sorrento Therapeutics, Inc.

People needed

96

Starts

2020-10-09

Expected to finish

2021-08-23

Last updated by the study team

2023-01-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed infection with SARS-CoV-2 per World Health Organization (WHO) criteria (including positive RT-PCR nucleic acid test of any specimen [eg, respiratory, blood, urine, stool, or other bodily fluid]) within 7 days of randomization
• Hospitalized with COVID-19 pneumonia (documented radiographically) and oxygen saturation <94% on room air or subject requires supplemental oxygen
• Able to swallow capsules
• Willing to follow contraception guidelines
• Subject or family member/caregiver must have provided written informed consent which includes signing the institutional review board approved consent form prior to participating in any study related activity. However, if obtaining written informed consent is not possible, other procedures as provided in the March 27th, 2020 FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic, Question 10, may be used

You may not qualify if…

• Known cardio-pulmonary resuscitation within 14 days prior to randomization
• Pregnant or breast feeding
• Suspected uncontrolled active bacterial, fungal, viral, or other infection (besides infection with SARS-CoV-2)
• Alanine aminotransferase (ALT) ≥ 3x upper limit of normal (ULN) and total bilirubin > 2x ULN
• QTcF prolongation >480 milliseconds
• Uncontrolled or untreated symptomatic arrhythmias, myocardial infarction within the last 6 weeks, or congestive heart failure (NYHA Grade 3 or 4). Exception: Subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll
• Treatment with a strong cytochrome P450 (CYP3A4 inhibitor (within 14 days before first dose of study drug) or inducer (within 7 days before first dose of study drug)
• Received anti-rejection or immunomodulatory drugs (eg, anti-cytokines, BTK inhibitors, JAK inhibitors, PI3K inhibitors) within 30 days before randomization on study
• Concurrent participation in another clinical trial involving therapeutic interventions (observational study participation is acceptable)
• Any condition that confounds the ability to interpret data from the study
• Relevant renal impairment (eGFR <60 mL/min)
• Any significant medical condition, laboratory abnormality or psychiatric illness that would interfere or prevent the subject from participating in the study

Where it is running

• MedStar Washington Hospital Center — Washington D.C., District of Columbia, United States
• Teradan Clinical Trials — Brandon, Florida, United States
• Alexandria Cardiology Clinic — Alexandria, Louisiana, United States
• Clinical Trials of SWLA — Lake Charles, Louisiana, United States
• Quality Clinical Research — Omaha, Nebraska, United States
• Memorial Hermann Memorial City Hospital — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.